Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)
Date
2016Author
Shapiro, Geoffrey
Wesolowski, Robert
Middleton, Mark
Devoe, Craig
Constantinidou, Anastasia
Papadatos-Pastos, Dionysios
Fricano, Marjorie
Zhang, Yanqiong
Karan, Sharon
Pollard, John
Penney, Marina
Asmal, Mohammed
Renshaw, F. Gary
Fields, Scott Z.
Yap, Timothy Anthony
Source
Cancer researchVolume
76Google Scholar check